Drug intelligence / Profile preview

recombinant human type III collagen

Development stage
Phase 2
Lead developer
Jinbo Biopharmaceutical
Modality
Recombinant Proteins and Enzymes
Administration
Intradermal, Injectable, Transdermal, Topical, Ophthalmic
01

Overview

Recombinant human type III collagen is a bioengineered protein that is structurally and functionally identical to native human type III collagen. It is produced by expressing the gene encoding the proalpha1 (III) chain in hosts such as Pichia pastoris yeast. This recombinant form avoids risks associated with animal-derived collagens—such as immunogenicity and pathogen transmission—and offers high purity and batch consistency[2][4][8]. Mechanistically, it can be taken up by fibroblasts where it promotes endogenous synthesis of natural type III collagen more than type I collagen, thereby reducing the ratio of type I/III collagens. This shift has been shown to improve hypertrophic scarring and support tissue regeneration[1][5]. Recombinant human type III collagen also supports cell proliferation and extracellular matrix replenishment; it has applications in dermatology (e.g., dermal fillers for wrinkle correction), wound healing, aesthetics (skin rejuvenation), rheumatology, ophthalmology, microneedles for drug delivery systems, and regenerative medicine[6][7][8][10].

Brand names
MEDICAL RECOMBINANT TYPE III HUMANIZED COLLAGEN REPAIR PATCH
Other names
recombinant humanized type III collagenrhCol IIIpro-collagen III alpha 1
02

Targets

ADGRG1Integrin (Integrin family)ITGA2/ITGB1 (Integrin alpha-2/beta-1 receptor)

Beyond the preview

Go deeper on recombinant human type III collagen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human type III collagen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call